Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron for prevention of etomidate-induced myoclonus during anesthesia induction
IRCT20190510043545N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of ondansetron in etomidate-induced myoclonus (EIM) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Incidence of myoclonic movements and Intensity of myoclonic movements. Started Oct 2021; status: completed.
02
Drugs
ondansetron
03
Conditions
etomidate-induced myoclonus (EIM)
Beyond the preview
Go deeper on IRCT20190510043545N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190510043545N2.